메뉴 건너뛰기




Volumn 4, Issue 4, 2007, Pages 236-242

New directions in the treatment of heart failure: Targeting free fatty acid oxidation

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; DOBUTAMINE; FATTY ACID; GLUCOSE; RANOLAZINE; TRIMETAZIDINE;

EID: 38049003591     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-007-0018-1     Document Type: Review
Times cited : (3)

References (79)
  • 1
    • 0030248160 scopus 로고    scopus 로고
    • Blood ketone bodies in congestive heart failure
    • Lommi J, Kupari M, Koskinen P, et al.: Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 1996, 28:665-672.
    • (1996) J Am Coll Cardiol , vol.28 , pp. 665-672
    • Lommi, J.1    Kupari, M.2    Koskinen, P.3
  • 2
    • 0027715375 scopus 로고
    • Metabolic response to graded exercise in chronic heart failure
    • Riley M, Bell N, Elborn JS, et al.: Metabolic response to graded exercise in chronic heart failure: Eur Heart J 1993, 14:1484-1488.
    • (1993) Eur Heart J , vol.14 , pp. 1484-1488
    • Riley, M.1    Bell, N.2    Elborn, J.S.3
  • 3
    • 0025772752 scopus 로고
    • Insulin resistance and hyperinsulinemia in patients with chronic heart failure
    • Paolisso G, De Riu S, Marrazzo G, et al.: Insulin resistance and hyperinsulinemia in patients with chronic heart failure. Metabolism 1991, 40:972-977.
    • (1991) Metabolism , vol.40 , pp. 972-977
    • Paolisso, G.1    De Riu, S.2    Marrazzo, G.3
  • 4
    • 0031024750 scopus 로고    scopus 로고
    • Glucose metabolism in the ischemic heart
    • Lopaschuck GD, Stanley WC: Glucose metabolism in the ischemic heart. Circulation 1997, 95:313-315.
    • (1997) Circulation , vol.95 , pp. 313-315
    • Lopaschuck, G.D.1    Stanley, W.C.2
  • 5
    • 0028255655 scopus 로고
    • Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans
    • Nuutila P, Knuuti MJ, Raitakari M, et al.: Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol 1994, 267:E941-E946.
    • (1994) Am J Physiol , vol.267
    • Nuutila, P.1    Knuuti, M.J.2    Raitakari, M.3
  • 6
    • 0036217052 scopus 로고    scopus 로고
    • Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes
    • Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002, 23:201-229.
    • (2002) Endocr Rev , vol.23 , pp. 201-229
    • Lewis, G.F.1    Carpentier, A.2    Adeli, K.3    Giacca, A.4
  • 7
    • 0035985081 scopus 로고    scopus 로고
    • Vascular function, insulin resistance and fatty acids
    • Steinberg HO, Baron AD: Vascular function, insulin resistance and fatty acids. Diabetologia 2002, 45:623-634.
    • (2002) Diabetologia , vol.45 , pp. 623-634
    • Steinberg, H.O.1    Baron, A.D.2
  • 8
    • 0034678082 scopus 로고    scopus 로고
    • The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase
    • Kantor PF, Lucien A, Kozak R, Lopashuck GD: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000, 86:580-588.
    • (2000) Circ Res , vol.86 , pp. 580-588
    • Kantor, P.F.1    Lucien, A.2    Kozak, R.3    Lopashuck, G.D.4
  • 9
    • 0028018335 scopus 로고
    • Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation
    • Fantini E, Demaison L, Sentex E, et al.: Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994, 26:949-958.
    • (1994) J Mol Cell Cardiol , vol.26 , pp. 949-958
    • Fantini, E.1    Demaison, L.2    Sentex, E.3
  • 10
    • 0141499890 scopus 로고    scopus 로고
    • Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase
    • Lopaschuk GD, Barr R, Thomas PD, Dyck JR: Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003, 93:e26-e32.
    • (2003) Circ Res , vol.93
    • Lopaschuk, G.D.1    Barr, R.2    Thomas, P.D.3    Dyck, J.R.4
  • 11
    • 0141723313 scopus 로고    scopus 로고
    • The antianginal trimetazidine does not exert its functional benefit via inhibition of mithocondrial long-chain 3-ketoacyl coenzyme A thiolase
    • MacInnes A, Fairman DA, Binding P, et al.: The antianginal trimetazidine does not exert its functional benefit via inhibition of mithocondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003, 93:e33-e37.
    • (2003) Circ Res , vol.93
    • MacInnes, A.1    Fairman, D.A.2    Binding, P.3
  • 12
    • 0025307724 scopus 로고
    • Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy
    • Brottier L, Barat JL, Combe C, et al.: Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990, 11:207-212.
    • (1990) Eur Heart J , vol.11 , pp. 207-212
    • Brottier, L.1    Barat, J.L.2    Combe, C.3
  • 13
    • 0032189888 scopus 로고    scopus 로고
    • Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease
    • Lu C, Dabrowski P, Fragasso G, Chierchia SL: Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998, 82:898-901.
    • (1998) Am J Cardiol , vol.82 , pp. 898-901
    • Lu, C.1    Dabrowski, P.2    Fragasso, G.3    Chierchia, S.L.4
  • 14
    • 0035208524 scopus 로고    scopus 로고
    • Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy
    • Belardinelli R, Purcaro A: Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001, 22:2164-2170.
    • (2001) Eur Heart J , vol.22 , pp. 2164-2170
    • Belardinelli, R.1    Purcaro, A.2
  • 15
    • 12744278944 scopus 로고    scopus 로고
    • Short and long term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy
    • Fragasso G, Piatti PM, Monti L, et al.: Short and long term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy. Am Heart J 2003, 146:E1-E8.
    • (2003) Am Heart J , vol.146
    • Fragasso, G.1    Piatti, P.M.2    Monti, L.3
  • 16
    • 2942512039 scopus 로고    scopus 로고
    • Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: A double-blind placebo-controlled study
    • Rosano GM, Vitale C, Sposato B, et al.: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003, 2:16.
    • (2003) Cardiovasc Diabetol , vol.2 , pp. 16
    • Rosano, G.M.1    Vitale, C.2    Sposato, B.3
  • 17
    • 4944224833 scopus 로고    scopus 로고
    • Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease
    • Vitale C, Wajngaten M, Sposato B, et al.: Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004, 25:1814-1821.
    • (2004) Eur Heart J , vol.25 , pp. 1814-1821
    • Vitale, C.1    Wajngaten, M.2    Sposato, B.3
  • 18
    • 12744261465 scopus 로고    scopus 로고
    • Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy
    • Di Napoli P, Taccardi AA, Barsotti A: Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005, 91:161-165.
    • (2005) Heart , vol.91 , pp. 161-165
    • Di Napoli, P.1    Taccardi, A.A.2    Barsotti, A.3
  • 19
    • 0023130780 scopus 로고
    • Anti-ischemia effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart
    • Lavanchy N, Martin J, Rossi A: Anti-ischemia effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987, 286:97-110.
    • (1987) Arch Int Pharmacodyn Ther , vol.286 , pp. 97-110
    • Lavanchy, N.1    Martin, J.2    Rossi, A.3
  • 20
    • 0026000171 scopus 로고
    • Detection of low PCr to ATP ratio in failing hypertrophied myocardium by 31P magnetic resonance spectroscopy
    • Conway MA, Allis J, Ouwerkerk R, et al.: Detection of low PCr to ATP ratio in failing hypertrophied myocardium by 31P magnetic resonance spectroscopy. Lancet 1991, 338:973-976.
    • (1991) Lancet , vol.338 , pp. 973-976
    • Conway, M.A.1    Allis, J.2    Ouwerkerk, R.3
  • 21
    • 0029034236 scopus 로고
    • Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy
    • Yabe T, Mitsunami K, Inubushi T, Kinoshita M: Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation 1995, 92:15-23.
    • (1995) Circulation , vol.92 , pp. 15-23
    • Yabe, T.1    Mitsunami, K.2    Inubushi, T.3    Kinoshita, M.4
  • 22
    • 0029800446 scopus 로고    scopus 로고
    • The creatine kinase system in failing and nonfailing human myocardium
    • Nascimben L, Ingwall JS, Pauletto P, et al.: The creatine kinase system in failing and nonfailing human myocardium. Circulation 1996, 94:1894-1901.
    • (1996) Circulation , vol.94 , pp. 1894-1901
    • Nascimben, L.1    Ingwall, J.S.2    Pauletto, P.3
  • 23
    • 33645466318 scopus 로고    scopus 로고
    • Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure
    • The results of this investigation confirm that partial fatty acid oxidation inhibition helps the failing myocardium to preserve its cellular energetic reserve
    • Fragasso G, De Cobelli F, Perseghin G, et al.: Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006, 27:942-948. The results of this investigation confirm that partial fatty acid oxidation inhibition helps the failing myocardium to preserve its cellular energetic reserve.
    • (2006) Eur Heart J , vol.27 , pp. 942-948
    • Fragasso, G.1    De Cobelli, F.2    Perseghin, G.3
  • 24
    • 0030819144 scopus 로고    scopus 로고
    • Myocardial phosphocreatine-to- ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy
    • Neubauer S, Horn M, Cramer M, et al.: Myocardial phosphocreatine-to- ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997, 96:2190-2196.
    • (1997) Circulation , vol.96 , pp. 2190-2196
    • Neubauer, S.1    Horn, M.2    Cramer, M.3
  • 25
    • 33747887613 scopus 로고    scopus 로고
    • A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure
    • This is the first study evaluating the effect of partial fatty acid oxidation inhibition in patients with heart failure of different etiologies
    • Fragasso G, Palloshi A, Puccetti P, et al.: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006, 48:992-998. This is the first study evaluating the effect of partial fatty acid oxidation inhibition in patients with heart failure of different etiologies.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 992-998
    • Fragasso, G.1    Palloshi, A.2    Puccetti, P.3
  • 26
    • 0036936426 scopus 로고    scopus 로고
    • Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure
    • Sabbah HN, Chandler MP, Mishima T, et al.: Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002, 8:416-422.
    • (2002) J Card Fail , vol.8 , pp. 416-422
    • Sabbah, H.N.1    Chandler, M.P.2    Mishima, T.3
  • 27
    • 0037163064 scopus 로고    scopus 로고
    • Short-term treatment with ranolazine improves mechanical efficacy in dogs with chronic heart failure
    • Chandler MP, Stanley WC, Morita H, et al.: Short-term treatment with ranolazine improves mechanical efficacy in dogs with chronic heart failure. Circ Res 2002, 91:278-280.
    • (2002) Circ Res , vol.91 , pp. 278-280
    • Chandler, M.P.1    Stanley, W.C.2    Morita, H.3
  • 28
    • 0028134824 scopus 로고
    • Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease
    • Hayashida W, van Eyll C, Rousseau MF, Pouleur H: Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994, 5:741-747.
    • (1994) Cardiovasc Drugs Ther , vol.5 , pp. 741-747
    • Hayashida, W.1    van Eyll, C.2    Rousseau, M.F.3    Pouleur, H.4
  • 29
    • 0029796954 scopus 로고    scopus 로고
    • Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction
    • Aaker A, McCormack JG, Hirai T, Musch TI: Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. J Cardiovasc Pharmacol 1996, 28:353-362.
    • (1996) J Cardiovasc Pharmacol , vol.28 , pp. 353-362
    • Aaker, A.1    McCormack, J.G.2    Hirai, T.3    Musch, T.I.4
  • 30
    • 0029746050 scopus 로고    scopus 로고
    • Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle
    • McCormack JG, Baracos VE, Barr R, Lopaschuk GD: Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. J Appl Physiol 1996, 81:905-910.
    • (1996) J Appl Physiol , vol.81 , pp. 905-910
    • McCormack, J.G.1    Baracos, V.E.2    Barr, R.3    Lopaschuk, G.D.4
  • 31
    • 8444242276 scopus 로고    scopus 로고
    • Uncoupling proteins in human heart
    • Murray AJ, Anderson RE, Watson GC, et al.: Uncoupling proteins in human heart. Lancet 2004 364:1786-1788.
    • (2004) Lancet , vol.364 , pp. 1786-1788
    • Murray, A.J.1    Anderson, R.E.2    Watson, G.C.3
  • 32
    • 8444246276 scopus 로고    scopus 로고
    • The metabolic vicious cycle in heart failure
    • Opie LH: The metabolic vicious cycle in heart failure. Lancet 2004, 364:1733-1734.
    • (2004) Lancet , vol.364 , pp. 1733-1734
    • Opie, L.H.1
  • 33
    • 34248226980 scopus 로고    scopus 로고
    • Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology
    • This is an official update on the therapeutic strategies in advanced heart failure
    • Metra M, Ponikowski O, Dickstein K, et al.: Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2007, 9:684-694. This is an official update on the therapeutic strategies in advanced heart failure.
    • (2007) Eur J Heart Fail , vol.9 , pp. 684-694
    • Metra, M.1    Ponikowski, O.2    Dickstein, K.3
  • 34
    • 0034086150 scopus 로고    scopus 로고
    • Relationship between endothelin-1 concentrations and the metabolic alterations typical of the insulin resistance syndrome
    • Piatti PM, Monti LD, Galli L, et al.: Relationship between endothelin-1 concentrations and the metabolic alterations typical of the insulin resistance syndrome. Metabolism 2000, 49:748-752.
    • (2000) Metabolism , vol.49 , pp. 748-752
    • Piatti, P.M.1    Monti, L.D.2    Galli, L.3
  • 35
    • 17744362283 scopus 로고    scopus 로고
    • Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes
    • Piatti PM, Monti LD, Zavaroni I, et al.: Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes. J Clin Endocrinol Metab 2000, 85:2416-2420.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 2416-2420
    • Piatti, P.M.1    Monti, L.D.2    Zavaroni, I.3
  • 36
    • 0019804810 scopus 로고
    • Insulin-resistance in heart and skeletal muscles of genetically obese Zucker rats
    • Crettaz M, Zaninetti D, Jeanrenaud B: Insulin-resistance in heart and skeletal muscles of genetically obese Zucker rats. Biochem Soc Trans 1981, 9:524-525.
    • (1981) Biochem Soc Trans , vol.9 , pp. 524-525
    • Crettaz, M.1    Zaninetti, D.2    Jeanrenaud, B.3
  • 37
    • 0030855598 scopus 로고    scopus 로고
    • Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension
    • Natali A, Taddei S, Quiñones Galvan A, et al.: Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. Circulation 1997, 96:725-726.
    • (1997) Circulation , vol.96 , pp. 725-726
    • Natali, A.1    Taddei, S.2    Quiñones Galvan, A.3
  • 38
    • 0029862973 scopus 로고    scopus 로고
    • Hyperinsulinemia as an independent risk factor for ischemic heart disease
    • Despres JP, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957.
    • (1996) N Engl J Med , vol.334 , pp. 952-957
    • Despres, J.P.1    Lamarche, B.2    Mauriege, P.3
  • 39
    • 0038681950 scopus 로고    scopus 로고
    • The relationship between insulin resistance and polymorphisms of the endothelial nitric oxide synthase gene in patients with coronary artery disease
    • Yoshimura T, Hisatomi A, Kajihara S, et al.: The relationship between insulin resistance and polymorphisms of the endothelial nitric oxide synthase gene in patients with coronary artery disease. J Atheroscler Thromb 2003, 10:43-47.
    • (2003) J Atheroscler Thromb , vol.10 , pp. 43-47
    • Yoshimura, T.1    Hisatomi, A.2    Kajihara, S.3
  • 40
    • 0033230056 scopus 로고    scopus 로고
    • Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries
    • Piatti PM, Fragasso G, Monti LD, et al.: Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. J Am Coll Cardiol 1999, 34:1452-1460.
    • (1999) J Am Coll Cardiol , vol.34 , pp. 1452-1460
    • Piatti, P.M.1    Fragasso, G.2    Monti, L.D.3
  • 41
    • 0242381316 scopus 로고    scopus 로고
    • Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting
    • Piatti P, Di Mario C, Monti LD, et al.: Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003, 108:2074-2081.
    • (2003) Circulation , vol.108 , pp. 2074-2081
    • Piatti, P.1    Di Mario, C.2    Monti, L.D.3
  • 42
    • 0000390475 scopus 로고    scopus 로고
    • Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe
    • Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999, 354:617-621.
    • (1999) Lancet , vol.354 , pp. 617-621
  • 43
    • 0035933194 scopus 로고    scopus 로고
    • Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure
    • Wallhaus TR, Taylor M, DeGrado TR, Russell DC: Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001, 103:2441-2446.
    • (2001) Circulation , vol.103 , pp. 2441-2446
    • Wallhaus, T.R.1    Taylor, M.2    DeGrado, T.R.3    Russell, D.C.4
  • 44
    • 0036932990 scopus 로고    scopus 로고
    • Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure
    • Podbregar M, Voga G: Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Card Fail 2002, 8:369-378.
    • (2002) J Card Fail , vol.8 , pp. 369-378
    • Podbregar, M.1    Voga, G.2
  • 45
    • 3142776467 scopus 로고    scopus 로고
    • Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial
    • Poole-Wilson PA, Swedberg K, Cleland JG, et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13.
    • (2003) Lancet , vol.362 , pp. 7-13
    • Poole-Wilson, P.A.1    Swedberg, K.2    Cleland, J.G.3
  • 46
    • 0346730904 scopus 로고    scopus 로고
    • Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)
    • Cohn JN, Pfeffer MA, Rouleau J, et al.: Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003, 5:659-667.
    • (2003) Eur J Heart Fail , vol.5 , pp. 659-667
    • Cohn, J.N.1    Pfeffer, M.A.2    Rouleau, J.3
  • 47
    • 33644760351 scopus 로고    scopus 로고
    • Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: Acute effects of the imidazoline I1-receptor agonist moxonidine
    • Mobini R, Fu M, Jansson PA, et al.: Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine. Clin Sci (Lond) 2006, 110:329-336.
    • (2006) Clin Sci (Lond) , vol.110 , pp. 329-336
    • Mobini, R.1    Fu, M.2    Jansson, P.A.3
  • 48
    • 2142641791 scopus 로고    scopus 로고
    • Trimetazidine diminishes fasting glucose in rats with fasting hyperglycemia: A preliminary study
    • Cano C, Bermudez VJ, Medina MT, et al.: Trimetazidine diminishes fasting glucose in rats with fasting hyperglycemia: a preliminary study. Am J Ther 2003, 10:444-446.
    • (2003) Am J Ther , vol.10 , pp. 444-446
    • Cano, C.1    Bermudez, V.J.2    Medina, M.T.3
  • 49
    • 33644878025 scopus 로고    scopus 로고
    • Metabolic and endothelial effects of trimetazidine on forearm muscle in patients with type 2 diabetes and ischemic cardiomyopathy
    • This study investigates the potential therapeutic value of partial fatty acid oxidation inhibition in diabetes mellitus
    • Monti LD, Setola E, Fragasso G, et al.: Metabolic and endothelial effects of trimetazidine on forearm muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab 2006, 290:E54-E59. This study investigates the potential therapeutic value of partial fatty acid oxidation inhibition in diabetes mellitus.
    • (2006) Am J Physiol Endocrinol Metab , vol.290
    • Monti, L.D.1    Setola, E.2    Fragasso, G.3
  • 50
    • 33846414720 scopus 로고    scopus 로고
    • Guidelines on diabetes, prediabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    • This is an official update on the therapeutic strategies in diabetes, prediabetes, and cardiovascular diseases
    • Ryden L, Standi E, Bartnik M: Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 2:88-136. This is an official update on the therapeutic strategies in diabetes, prediabetes, and cardiovascular diseases.
    • (2007) Eur Heart J , vol.2 , pp. 88-136
    • Ryden, L.1    Standi, E.2    Bartnik, M.3
  • 51
    • 0037028648 scopus 로고    scopus 로고
    • Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: Evaluation of the protective role of the metabolic modulator trimetazidine
    • Fragasso G, Piatti P, Monti L, et al.: Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine. J Am Coll Cardiol 2002, 39:413-419.
    • (2002) J Am Coll Cardiol , vol.39 , pp. 413-419
    • Fragasso, G.1    Piatti, P.2    Monti, L.3
  • 52
    • 0033609032 scopus 로고    scopus 로고
    • Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: Increase in endothelin production in the heart and beneficial effect of endothelin A antagonist on survival and cardiac function
    • Yamauchi-Kohno R, Miyauchi T, Hoshino T, et al.: Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin production in the heart and beneficial effect of endothelin A antagonist on survival and cardiac function. Circulation 1999, 99:2171-2176.
    • (1999) Circulation , vol.99 , pp. 2171-2176
    • Yamauchi-Kohno, R.1    Miyauchi, T.2    Hoshino, T.3
  • 53
    • 0021961392 scopus 로고
    • Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells
    • Maridonneau-Parini I, Harpey C: Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985, 20:148-151.
    • (1985) Br J Clin Pharmacol , vol.20 , pp. 148-151
    • Maridonneau-Parini, I.1    Harpey, C.2
  • 54
    • 0348129532 scopus 로고    scopus 로고
    • Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial
    • Chaitman BR, Pepine CJ, Parker JO, et al.: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004, 291:309-316.
    • (2004) JAMA , vol.291 , pp. 309-316
    • Chaitman, B.R.1    Pepine, C.J.2    Parker, J.O.3
  • 55
    • 28944448286 scopus 로고    scopus 로고
    • Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
    • Timmis AD, Chaitman BR, Crager M: Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006, 27:42-48.
    • (2006) Eur Heart J , vol.27 , pp. 42-48
    • Timmis, A.D.1    Chaitman, B.R.2    Crager, M.3
  • 56
    • 0024262853 scopus 로고
    • Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine
    • Lopashuck GD, Wall SR, Olley PM, Davies NJ: Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988, 63:1036-1043.
    • (1988) Circ Res , vol.63 , pp. 1036-1043
    • Lopashuck, G.D.1    Wall, S.R.2    Olley, P.M.3    Davies, N.J.4
  • 57
    • 0025991923 scopus 로고
    • Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus
    • Ratheiser K, Schneeweiss B, Waldhausl W, et al.: Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. Metabolism 1991, 40:1185-1190.
    • (1991) Metabolism , vol.40 , pp. 1185-1190
    • Ratheiser, K.1    Schneeweiss, B.2    Waldhausl, W.3
  • 58
    • 0030778603 scopus 로고    scopus 로고
    • Etomoxir improves left ventricular performance of pressure-overloaded rat heart
    • Turcani M, Rupp H: Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 1997, 96:3681-3686.
    • (1997) Circulation , vol.96 , pp. 3681-3686
    • Turcani, M.1    Rupp, H.2
  • 59
    • 0036195453 scopus 로고    scopus 로고
    • Therapeutic potential of CPT I inhibitors: Cardiac gene transcription as a target
    • Zarain-Herzberg A, Rupp H: Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin Investig Drugs 2002, 11:345-356.
    • (2002) Expert Opin Investig Drugs , vol.11 , pp. 345-356
    • Zarain-Herzberg, A.1    Rupp, H.2
  • 60
    • 0033910352 scopus 로고    scopus 로고
    • First clinical trial with etomoxir in patients with chronic congestive heart failure
    • Schmidt-Schweda S, Holubarsch C: First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000, 99:27-35.
    • (2000) Clin Sci , vol.99 , pp. 27-35
    • Schmidt-Schweda, S.1    Holubarsch, C.2
  • 61
    • 0029587279 scopus 로고
    • Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor etomoxir
    • Schmitz FJ, Rosen P, Reinauer H: Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor etomoxir. Horm Metab Res 1995, 27:515-522.
    • (1995) Horm Metab Res , vol.27 , pp. 515-522
    • Schmitz, F.J.1    Rosen, P.2    Reinauer, H.3
  • 62
    • 0142060197 scopus 로고    scopus 로고
    • Downregulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy
    • Cabreros A, Merlos M, Laguna JC, Carrera MV: Downregulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy. J Lipid Res 2003, 44:388-398.
    • (2003) J Lipid Res , vol.44 , pp. 388-398
    • Cabreros, A.1    Merlos, M.2    Laguna, J.C.3    Carrera, M.V.4
  • 63
    • 0035996062 scopus 로고    scopus 로고
    • Etomoxir-induced oxidative stress in HepG2 cells detected by differential gene expression is confirmed biochemically
    • Merril CL, Ni H, Yoon LW, et al.: Etomoxir-induced oxidative stress in HepG2 cells detected by differential gene expression is confirmed biochemically. Toxicol Sci 2002, 68:93-101.
    • (2002) Toxicol Sci , vol.68 , pp. 93-101
    • Merril, C.L.1    Ni, H.2    Yoon, L.W.3
  • 64
    • 0033653158 scopus 로고    scopus 로고
    • Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart
    • Kennedy JA, Kiosoglous AJ, Murphy GA, et al.: Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2000, 36:794-801.
    • (2000) J Cardiovasc Pharmacol , vol.36 , pp. 794-801
    • Kennedy, J.A.1    Kiosoglous, A.J.2    Murphy, G.A.3
  • 65
    • 0028953680 scopus 로고
    • Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate
    • Jeffrey FM, Alvarez L, Diczku V, et al.: Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 1995, 25:469-472.
    • (1995) J Cardiovasc Pharmacol , vol.25 , pp. 469-472
    • Jeffrey, F.M.1    Alvarez, L.2    Diczku, V.3
  • 66
    • 0021864482 scopus 로고
    • Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine
    • Stephens TW, Higgins AJ, Cook GA, Harris RA: Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem J 1985, 227:651-660.
    • (1985) Biochem J , vol.227 , pp. 651-660
    • Stephens, T.W.1    Higgins, A.J.2    Cook, G.A.3    Harris, R.A.4
  • 67
    • 0019122736 scopus 로고
    • Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris
    • Bergman G, Atkinson L, Metcalfe J, et al.: Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris. Eur Heart J 1980, 1:247-253.
    • (1980) Eur Heart J , vol.1 , pp. 247-253
    • Bergman, G.1    Atkinson, L.2    Metcalfe, J.3
  • 68
    • 0025343177 scopus 로고
    • Efficacy and safety of perhexiline maleate in refractory angina: A double-blind placebo-controlled clinical trial of a novel antianginal agent
    • Cole PL, Beamer AD, McGowan N, et al.: Efficacy and safety of perhexiline maleate in refractory angina: a double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990, 81:1260-1270.
    • (1990) Circulation , vol.81 , pp. 1260-1270
    • Cole, P.L.1    Beamer, A.D.2    McGowan, N.3
  • 69
    • 33644875657 scopus 로고    scopus 로고
    • Lee L, Campbell R, Scheuermann-Freestone M, et al.: Metabolic modulation with perhexiline in chronic heart failure. A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005, 112:3280-3288. This study shows that in chronic heart failure, fatty acid oxidation inhibition is beneficial even through other mechanisms of action.
    • Lee L, Campbell R, Scheuermann-Freestone M, et al.: Metabolic modulation with perhexiline in chronic heart failure. A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005, 112:3280-3288. This study shows that in chronic heart failure, fatty acid oxidation inhibition is beneficial even through other mechanisms of action.
  • 70
    • 0022508927 scopus 로고
    • Perhexiline-induced lipidosis in the dark Agouti (DA) rat. An animal model of genetically determined neurotoxicity
    • Meier C, Wahllaender A, Hess CW, Preisig R: Perhexiline-induced lipidosis in the dark Agouti (DA) rat. An animal model of genetically determined neurotoxicity. Brain 1986, 109:649-660.
    • (1986) Brain , vol.109 , pp. 649-660
    • Meier, C.1    Wahllaender, A.2    Hess, C.W.3    Preisig, R.4
  • 71
    • 0007619884 scopus 로고    scopus 로고
    • Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease
    • Killalea SM, Krum H: Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001, 1:193-204.
    • (2001) Am J Cardiovasc Drugs , vol.1 , pp. 193-204
    • Killalea, S.M.1    Krum, H.2
  • 72
    • 0035134803 scopus 로고    scopus 로고
    • A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction
    • Steg PG, Grollier G, Gallay P, et al.: A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 2001, 77:263-273.
    • (2001) Int J Cardiol , vol.77 , pp. 263-273
    • Steg, P.G.1    Grollier, G.2    Gallay, P.3
  • 73
    • 0030602869 scopus 로고    scopus 로고
    • The effect of trimetazidine on reperfusion arrhythmia in acute myocardial infarction
    • Papadopoulos CL, Kanonidis IE, Kotridis PS, et al.: The effect of trimetazidine on reperfusion arrhythmia in acute myocardial infarction. Int J Cardiol 1996, 55:137-142.
    • (1996) Int J Cardiol , vol.55 , pp. 137-142
    • Papadopoulos, C.L.1    Kanonidis, I.E.2    Kotridis, P.S.3
  • 74
    • 0032858431 scopus 로고    scopus 로고
    • Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: Short-term and long term results
    • Di Pasquale P, Lo Verso P, Bucca V, et al.: Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long term results. Cardiovasc Drug Ther 1999, 13:423-428.
    • (1999) Cardiovasc Drug Ther , vol.13 , pp. 423-428
    • Di Pasquale, P.1    Lo Verso, P.2    Bucca, V.3
  • 75
    • 0026759485 scopus 로고
    • Cardioprotective effect of trimetazidine during coronary artery graft surgery
    • Fabiani JN, Ponzio O, Emerit I, et al.: Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg 1992, 33:486-491.
    • (1992) J Cardiovasc Surg , vol.33 , pp. 486-491
    • Fabiani, J.N.1    Ponzio, O.2    Emerit, I.3
  • 76
    • 0026699975 scopus 로고
    • Myocardial protection during percutaneous transluminal angioplasty: Effects of trimetazidine
    • Kober G, Buck T, Sievert H, et al.: Myocardial protection during percutaneous transluminal angioplasty: effects of trimetazidine. Eur Heart J 1992, 13:1109-1115.
    • (1992) Eur Heart J , vol.13 , pp. 1109-1115
    • Kober, G.1    Buck, T.2    Sievert, H.3
  • 77
    • 34249283806 scopus 로고    scopus 로고
    • Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention
    • Preventive partial inhibition of fatty acid oxidation could be particularly beneficial in patients undergoing percutaneous coronary interventions
    • Bonello L, Sbragia P, Amabile N, et al.: Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 2007, 93:703-707. Preventive partial inhibition of fatty acid oxidation could be particularly beneficial in patients undergoing percutaneous coronary interventions.
    • (2007) Heart , vol.93 , pp. 703-707
    • Bonello, L.1    Sbragia, P.2    Amabile, N.3
  • 78
    • 0042859821 scopus 로고    scopus 로고
    • Role of the mitochondrial permeability transition in myocardial disease
    • Weiss JN, Korge P, Honda HM, et al: Role of the mitochondrial permeability transition in myocardial disease. Circ Res 2003, 93:292-301.
    • (2003) Circ Res , vol.93 , pp. 292-301
    • Weiss, J.N.1    Korge, P.2    Honda, H.M.3
  • 79
    • 27644492930 scopus 로고    scopus 로고
    • Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury
    • Argaud L, Gomez L, Gateau-Roesch O, et al.: Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005, 39:893-899.
    • (2005) J Mol Cell Cardiol , vol.39 , pp. 893-899
    • Argaud, L.1    Gomez, L.2    Gateau-Roesch, O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.